American City Business Journals3 months ago
Summit, New Jersey-based Celgene (Nasdaq: CELG) has filed a patent infringement lawsuit against Synthon over generic versions of Celgene’s valuable multiple myeloma drug products. While patent infringement suits against generic companies have remained common, the U.S. Food and Drug Administration has made recent statements about encouraging competition through timely market entry of generics. The lawsuit – filed in the U.S. District Court for the Middle District of North Carolina – names Synthon Pharmaceuticals, Synthon B.V., Synthon C.R.O. and Alvogen Pine Brook as defendants in the case.